Pharmaceuticals: Antimicrobial Peptides in 2014

Pharmaceuticals 2015, 8, 123-150; doi:10.
3390/ph8010123
OPEN ACCESS
pharmaceuticals
ISSN 1424-8247
www.mdpi.com/journal/pharmaceuticals
Review
Antimicrobial Peptides in 2014

Guangshun Wang 1,*, Biswajit Mishra 1, Kyle Lau 1, Tamara Lushnikova 1, Radha Golla 1
and Xiuqing Wang 1,2
1
Department of Pathology and Microbiology, University of Nebraska Medical Center,
986495 Nebraska Medical Center, Omaha, NE 68198-6495, USA
2
Institute of Clinical Laboratory, Ningxia Medical University, Yinchuan 750004, China
* Author to whom correspondence should be addressed; E-Mail: [email protected];

Tel.: +402-559-4176; Fax: +402-559-4077.
Academic Editor: Jean Jacques Vanden Eynde
Received: 11 February 2015 / Accepted: 17 March 2015 / Published: 23 March 2015
Abstract: This article highlights new members, novel mechanisms of action, new functions,
and interesting applications of antimicrobial peptides reported in 2014. As of December
2014, over 100 new peptides were registered into the Antimicrobial Peptide Database,
increasing the total number of entries to 2493. Unique antimicrobial peptides have been
identified from marine bacteria, fungi, and plants. Environmental conditions clearly
influence peptide activity or function. Human α-defensin HD-6 is only antimicrobial under
reduced conditions. The pH-dependent oligomerization of human cathelicidin LL-37 is
linked to double-stranded RNA delivery to endosomes, where the acidic pH triggers the
dissociation of the peptide aggregate to release its cargo. Proline-rich peptides, previously
known to bind to heat shock proteins, are shown to inhibit protein synthesis. A model
antimicrobial peptide is demonstrated to have multiple hits on bacteria, including surface
protein delocalization. While cell surface modification to decrease cationic peptide binding
is a recognized resistance mechanism for pathogenic bacteria, it is also used as a survival
strategy for commensal bacteria. The year 2014 also witnessed continued efforts in
exploiting potential applications of antimicrobial peptides. We highlight 3D structure-based
design of peptide antimicrobials and vaccines, surface coating, delivery systems, and
microbial detection devices involving antimicrobial peptides. The 2014 results also support
that combination therapy is preferred over monotherapy in treating biofilms.
Pharmaceuticals 2015, 8 124
Keywords: antimicrobial peptide; bacterial detection; biofilms; mechanism of action;

nanoparticle; peptide discovery; sensors; structure-based design; surface coating
1. Introduction
Antimicrobial peptides, or host defense peptides, are important components of innate immune systems.
This field is currently moving rapidly. On one hand, there is an urgent demand for novel antimicrobials
due to the current trend of reduction in the potency of commonly used antibiotics. On the other hand,
our research now pays more attention to innate immune systems where antimicrobial peptides play an
essential role. An imbalanced expression of antimicrobial peptides has been implicated in human
disease [1–5]. All these research activities around the world led to a substantial increase in the number
of scientific papers on antimicrobial peptides. In 2014 alone, a search of the PubMed using “antimicrobial
peptides and 2014” returned 7562 publications (~20 articles per day) [6]. About 10% of these
publications are review articles. However, a summary in the style of annual report is lacking. During our
regular update of the Antimicrobial Peptide Database (APD) (http://aps.unmc.edu/AP) [7–9] in the past
years, we noticed new peptides of outstanding interest and created a website for them
(http://aps.unmc.edu/AP/timeline.php) [10]. We also felt the need to write a story on these interesting
molecules. Since the antimicrobial peptide field is rather broad, a detailed report on every aspect of the
research is out of the scope of this review. Instead, we chose to highlight the antimicrobial peptide
research by focusing on the following topics: (1) Of the new peptides discovered in 2014, are there any
unique members that expand our current knowledge of natural antimicrobial peptides? (2) For known
peptides, have we uncovered new functions that fill in our knowledge gap? (3) What progress have we
made in mechanistic studies? Have any of our existing views been challenged? What about the genetic
basis of bacterial resistance? (4) Are there advances in peptide applications? In the following, we discuss
these four aspects of the antimicrobial peptide research based on the new discoveries made during 2014.
We apologize if your important work did not fit into the scope of this article or escaped our attention.
2. New Host Defense Peptides Reported in 2014
This section features new antimicrobial peptides discovered in 2014. Two major methods were
utilized for peptide discovery: a combination of chromatographic approaches [11–21] and genomic and
proteomic approaches [22–25]. The proteomic approach has the potential of identifying a large number
of peptides. However, we only registered peptides into the APD database if they have a known amino
acid sequence (usually less than 100 amino acids) and demonstrated antimicrobial activity. In 2014,
104 new antimicrobial peptides were registered in the APD [7,8]. This 2014 total is comparable to those
annual totals of peptides (over 100) collected into the APD since 2000 [26]. In the following, we
highlight unique peptides from various life kingdoms.
Of the 104 new antimicrobial peptides, 29 bacteriocins (i.e., bacterial antimicrobial peptides) were
isolated from the bacterial kingdom. The peptide BacFL31 is unusual in that its N-terminal amino acid
sequence contains six hydroxyprolines (X in the sequence GLEESXGHXGQXGPXGPXGAXGP) [11].
Baceridin, a non-ribosomally synthesized circular peptide with only six amino acids (50% D-amino
acids), was isolated from a plant-associated Bacillus strain [12]. This peptide can inhibit cell cycle
progression and causes apoptosis in cancer cells independent of p53. It is the most hydrophobic peptide
(100%) and the shortest circular peptide in the APD (Table 1). Lassomycin was found to be similar to
lassos since its aspartic acid 8 forms a bond with the N-terminal glycine. This peptide kills
Mycobacterium tuberculosis by binding to ATP-dependent protease ClpC1P1P2 [13]. It is exciting that
humans have reached organisms deep in the sea. Using transformation-associated recombination (TAR)
technology, Yamanaka et al. succeeded in cloning and expression of a silent lipopeptide biosynthetic
gene cluster from the marine actinomycete Saccharomonospora sp. CNQ-490 to produce taromycin A,
a daptomycin analog [14]. In addition, several lipopeptides were found from a marine bacterium Bacillus
subtilis. One of them, gageotetrin A, consists of only leucine and glutamic acid followed by a new fatty
acid 3-hydroxy-11-methyltridecanoic acid at the C-terminus [27]. Interestingly, these peptides displayed
rather good antibacterial activity (0.01–0.06 µM) against Staphylococcus aureus, B. subtilis, Salmonella
typhimurium, Pseudomonas aeruginosa, Rhizoctonia solani, Colletotrichum acutatum, and Botrytis
cinera. Although gageotetrin A is a conjugate, it possesses the shortest peptide sequence (Table 1) in the
APD. The structure of anionic gageotetrin A (peptide + fatty acid) is clearly different from synthetic
ultra-short lipopeptides (fatty acid + peptide), which are usually cationic to mimic cationic antimicrobial
peptides [28]. Gageotetrin A has a simpler molecular design compared to anionic daptomycin, the first
lipopeptide antimicrobial approved by FDA in 2003 [29]. Another peptide, sonorensin with broad activity
spectrum against both Gram-positive and Gram-negative bacteria, was also identified from a marine
bacterium Bacillus sonorensis MT93. It possesses a unique amino acid sequence with multiple copies
of the CWSCXGHS motif, where X is methionine or alanine (Table 1). Sonorensin is the first
characterized bacteriocin from the heterocycloanthracin subfamily [30]. These successful examples
prove that it is likely to identify novel antimicrobial peptides from unexplored organisms.
The discovery of new antimicrobial peptides from the fungal kingdom is lagging behind other life
kingdoms. In 2014, we collected only one defensin-like peptide from Coprinopsis cinerea. Like fungal
plectasin and eurocin [31,32], copsin inhibited cell wall synthesis by binding to lipid II [33]. These
fungal peptides share the same 3D fold, comprising one α-helix packed with a two-stranded -sheet.
Differing from plectasin and eurocin with three disulfide bonds, however, copsin is stabilized by six
disulfide bonds. In addition, the N-terminus of copsin is modified into a pyroglutamate (17 peptides in
the APD with such a modification [8]), furthering conferring stability to the peptide against high
temperatures and protease digestion. Thus, fungi constitute yet another important kingdom for novel
antimicrobial discovery.
In 2014, five new antimicrobial peptides were characterized from the plant kingdom and one of them
is quite unique. Different from many disulfide bond stabilized defensins with a β-sheet structure,
EcAMP3 is a disulfide-stabilized hairpin-like α-helical peptide. It is the first such peptide that inhibits
phytopathogenic bacteria [20]. Hispidalin from winter melon Benincasa hispida [34] shows only 31%
sequence similarity to tachycitin from horseshoe crabs [35] and amphibian brevinin-1PRb [36] based on
sequence alignment in the APD [7]. Since hispidalin is a newly discovered peptide, it has not been
trained in the existing programs. Not surprising, several online machine-learning programs were unable
to predict it as an antimicrobial peptide [37–39].
Table 1. Select antimicrobial peptides discovered in 2014.

APD ID Name Source Peptide amino acid sequence Unique features 1
2381 Gageotetrin A Bacteria LE The shortest lipopeptide
CWSCMGHSCWSCMGHSC
WSCAGHSCWSCMGHSCWS Repeating CWSCXGHS
2397 Sonorensin Bacteria
CMGHSCWSCAGHCCGSCW motif
HGGM
The shortest circular peptide
2372 Baceridin Bacteria WAIVLL consisting entirely of
hydrophobic amino acids
QNCPTRRGLCVTSGLTACR
The first fungal defensin
2440 Copsin Fungi NHCRSCHRGDVGCVRCSN
with six disulfide bonds
AQCTGFLGTTCTCINPCPRC
A unique peptide with 31%
SDYLNNNPLFPRYDIGNVEL
similarity to known
2407 Hispidalin Plants STAYRSFANQKAPGRLNQN
sequences. Not predicted by
WALTADYTYR
existing programs
The first disulfide-stabilized
GADRCRERCERRHRGDWQ hairpin-like helical peptide
2477 EcAMP3 Plants
GKQRCLMECRRREQEED that inhibits
phytopathogenic bacteria
KRFKKFFKKVKKSVKKRLK
2424 Crotalicidin Animals Rich in lysine (38%)
KIFKKPMVIGVTIPF
1
Additional peptide properties can be found in the APD database (http://aps.unmc.edu/AP) [8] using peptide
ID in the table. A full list of the 2014 antimicrobial peptides can also be studied there.
Of the 104 antimicrobial peptides found in 2014, 69 originated from animals. This is consistent with
the overall picture in the APD that antimicrobial peptides from the animal kingdom dominate [26].
Moreover, amphibians remain a major source for discovering natural antimicrobial peptides, accounting
for 35% of the 2014 total (38.8% of the entire database entries). Most of these new sequences resemble
the known frog antimicrobial peptides, which are linear and have the potential to form a helical
structure [18,19]. Although cathelicidins have been identified from a variety of animals, ranging from
birds, fish, and reptiles, to mammals [40], candidates from amphibians were not reported until 2012 [41].
In 2014, two new members appeared [42], leading to a total of six amphibian cathelicidins in the APD
(five helical and one glycine-rich). These cathelicidins are quite distinct from the main body of amphibian
peptides. For example, cathlicidin RC-1 has a high content of lysines (32%). Crotalicidin [17], a
homologous snake cathelicidin, contains an even higher content of lysines (38%) (Table 1).
Also in 2014, some known human peptides or proteins were demonstrated to be antimicrobial. These
include human α-defensin 6 (HD-6), β-defensin 120 (DEFB120), chemokine CCL24 (eotaxin-2), CCL26
(eotaxin-3), and human ribonuclease 6 (RNase 6). While HD-6 is active against Bifidobacterium
adolescentis [43], recombinant DEFB120 is active against Escherichia coli, S. aureus, and Candida
albicans [44]. Eotaxin-1 (CCL11), eotaxin-2, and eotaxin-3 are known chemokines, which are also
active against the airway pathogens Streptococcus pneumoniae, S. aureus, Haemophilus influenzae, and
P. aeruginosa [45]. In addition, human RNase 6 is inducible and shows activity against uropathogens,
underscoring its defense role in the urinary tract [46]. These characterized members further expand the
known reservoir of human host defense peptides and proteins reviewed in 2014 [47].
3. New Light on Known Human Antimicrobial Peptides
Antimicrobial peptides may be constitutively expressed to keep defined loci in a healthy state [1,48].
Compared to neonatal and adult keratinocytes, the corresponding fetal cells express much more human
antimicrobial peptides for host defense [49]. Alternatively, these molecules can also be induced upon
bacterial invasion. For example, a human cathelicidin peptide is induced in skin fat cells upon S. aureus
infection, underscoring the significance of adipocytes in host defense [50]. Previously, Gallo and
colleagues also found that overexpression of cathelicidin PR-39 protected animals from group A
Streptococcus (GAS) infection [51]. Interestingly, the gut possesses both constitutively expressed and
induced antimicrobial peptides. While human cathelicidin LL-37 and β-defensins 2-4 (hBD-2 to
HBD-4) are induced, human α-defensin 5 (HD-5), HD-6, and β-defensin 1 (hBD-1) are constitutively
expressed [52]. These constitutively expressed human peptides also play a special role in host defense.
In 2014, HD-5 was shown to be especially potent against the most virulent form of Clostridium difficile,
thereby preventing its infection of small intestine. This is a significant observation considering that
C. difficile can evade the action of other host microbicidal peptides and disturb the balance of gut
microbiota [53]. Human papillomavirus (HPV) infections can lead to cervical cancer and HD-5 can
prevent viral entry [54]. In addition, Wiens and Smith showed that HD-5 directly interferes with a critical
host-mediated viral processing step, furin cleavage of L2, at the cell surface [55]. Structurally, HD-5 can
form a disulfide bond swapped dimer in vitro [56]. It should be interesting to test whether this dimer is
linked to host defense in vivo.
How HD-6 plays the defense role in human gut has been puzzling for years. Similar to human
hBD-1 [57], Schroeder et al. found that human Paneth cell HD-6 only exerted antibacterial activity under
reduced conditions, establishing it as a bona fide antimicrobial peptide [43]. This reduction may be
achieved in vivo by the NADPH thioredoxin-reductase system. In vitro, removal of the N-terminal two
amino acid residues of HD-6 enabled a full reduction by dithiothreitol without influencing its activity.
Such a truncated form was isolated previously from ileal neobladder urine [58]. In addition, HD-6 can
form neutrophil extracellular traps (NETs) to trap invading microbes [59]. Thus, recent breakthroughs
have uncovered two possible mechanisms for HD-6 in host defense.
The importance of environmental conditions for antimicrobial activity is not limited to α-defensins.
In 2014, Abou Alaiwa et al. showed that the composition of the airway surface liquid is critical for
human LL-37 and hBD-3 to kill inhaled and aspirated bacteria. A decrease in pH from 8 to 6.8 in
pulmonary airway reduced the activity of both peptides against S. aureus as well as synergistic effects
between innate immune peptides [60].
It is known that pH modulates the oligomerization state of human LL-37. At acidic pH, LL-37 is
monomeric; it aggregates at physiological pH [61]. The mode of oligomerization was also studied
in 2014 by using disulfide-linked dimers [62]. NMR studies confirmed this pH-dependent
phenomenon [63]. However, the link of this phenomenon to biology was not clear. In 2014, Gao and
colleagues reported that LL-37 enhancement of signal transduction by Toll-like receptor 3 (TLR3) is
regulated by pH [64]. Upon acidification in endosomes, oligomerized LL-37 dissociates, allowing the
release of delivered dsRNA to act as an agonist for TLR3 signaling. In contrast, LL-29, a natural fragment
of human LL-37 that lacks the C-terminal portion [65], is unable to do so. Since our previous NMR studies
found that nearly all the residues of LL-37 (residues 1-36) are involved in oligomerization [63,66],
the C-terminal portion of LL-37 might be involved in the tetramer formation of LL-37. The salt bridges,
likely involving R34 and/or E36, can be disrupted at acidic pH, providing a molecular basis for
pH-dependent oligomer dissociation and dsRNA release.
All these examples above underscore that environmental conditions are an important mediator of the
function of antimicrobial peptides. There are also other mediators that regulate peptide activity, including
proteases, metals, salts, and chemical modifications. While 3D triple-resonance NMR studies show that
the helical region (residues 2-31) of LL-37 is responsible for both membrane and lipopolysaccharides
(LPS) binding [63], citrullination of arginines can reduce its ability in preventing endotoxin-induced
sepsis [67]. Likewise, ADP-ribosylation of four out of the five arginines of human LL-37 may regulate
this property [68]. A more recent discovery reveals that during S. aureus invasion, skin adipocytes can
replicate rapidly and produce a cathelicidin peptide longer than LL-37 to prevent infection [50].
Previously, a different form of human cathelicidin, ALL-38, was also isolated from the human
reproductive system [69]. Therefore, human proteases at a defined location play an important role in
determining the exact molecular form of mature antimicrobial peptides required for host defense [47].
4. Mechanisms of Action of Antimicrobial Peptides and Genetic Basis of Bacterial Resistance
4.1. Peptide at Work
Although there are anionic peptides, natural antimicrobial peptides are usually cationic with an
average net charge of +3.2 [7,8]. A leading view is that these cationic peptides target negatively charged
bacterial membranes. However, other mechanisms are possible [4,5,47,63]. In the case of membrane
targeting, how it damages the membranes remains debatable. A variety of possible membrane-weakening
mechanisms have been summarized by Vogel [70] and three of them are depicted in Figure 1. These
models are helpful and may inspire the design of new experiments to check their validity. In the carpet
model [71], antimicrobial peptides are assumed to locate on the membrane surface. Is the peptide flat?
In 2014, solid-state NMR studies of piscidins revealed peptide tilting to achieve an optimal interaction.
The extent of tilting depends on both peptide sequence and lipid composition. The glycine at position
13 may be important for peptide plasticity [72]. Numerous peptide examples, including human
cathelicidin LL-37 [66], possess a similar glycine that may modulate peptide activity against different
bacteria. However, there are only a few examples with a defined pore. Structural determination yielded
evidence for channel or pore formation. Gramicidin and alamethicin are two known examples [73,74].
Recently, the crystal structure of human dermcidin implies another possible channel [75,76]. In 2014,
a C-type lectin is proposed to form a pore in bacterial membranes based on a combined structural
determination by X-ray diffraction with electron microscopy data. In this model, six copies of human
RegIIIα assemble into a ring structure with a hole in the center [77].
Figure 1. Mechanisms of action of antimicrobial peptides in 2014. Membrane channel

formation (A) is proposed for dermicidin [76] and transmembrane pore formation for
C-type lectin RegIIIα [77]. While human LL-37 [78] may form a toroidal pore (B), it started
with a carpet model [79] (C) where antimicrobial peptides such as piscidins [72] are located
on the membrane surface. Receptor mediated binding was observed for Lactococcin G and
Enterocin 1071, which bind to UppP, an enzyme involved in cell wall synthesis (D) [80]. In
addition, Gravicin ML binds to maltose ABC receptors (E) [81]. Further, RTD2, as well as
lantibiotic Pep5, interacts with membranes causing the release of autolysin (F) [82]. Beyond
membranes, bacterial MccJ25 could inhibit RNA polymerase (G) [83], while apidaecins,
oncocins [84] and Bac7 [85] inhibit protein synthesis by binding to ribosomal proteins (H).
Abbreviations used in the figures are OM, outer membrane; IM, inner membrane; PGN,
peptidoglycan; LTA, lipoteichoic acid; MLT, maltose transporter. In addition, refer to the text.
Human α-defensin HNP1 and β-defensin hBD-3 are known to inhibit cell wall synthesis [86,87].
What about -defensins [16]? In 2014, Selsted and colleagues asked this question. In collaboration with
Sahl, they found that RTD-2 did not bind to lipid II. Rather, it interacted with bacterial membranes
in the presence of glucose. In addition, they detected the release of peptidoglycan lytic enzymes
(or autolysins) by S. aureus. Interestingly, bacterial lantibiotic Pep5 can work in the same manner [82].
There is precedence for such a similarity. Like defensins, it is common for lantibiotics to inhibit cell wall
synthesis by binding to lipid II [88]. In addition, some lantibitics and cyclotides share the same
phosphatidylethanolamine (PE) lipid target [89,90]. Such a cyclotide binding to PE-rich membrane rafts
is proposed to be responsible for activity against cancer and HIV-1 [91]. The similarity between
cyclotides and lantibiotics was initially suggested by their similar amino acid composition plots [63].
The mechanistic similarities between thioether bonded lantibiotics and disulfide bonded defensing-like
peptides are remarkable (Table 2), supporting a recent universal peptide classification that groups them
into one big class: sidechain-sidechain linked peptides [9].
Table 2. Mechanistic similarities between thioether-bonded lantibiotics and disulfide-boned peptides.

Mechanism Lantibiotic Examples Disulfide-Linked Examples
Nisin A, lacticin 3147, HNP1, hBD-3, plectasin,
Inhibition of cell wall synthesis 1
mersacidin, bovicin HJ50 lucifensin, eurocin, copsin
Membrane and autolysin release Pep5 -defensins such as RTD-2
Binding to lipid PE Duramycins, cinnamycin Kalata B1, cycloviolacin O2
1
Selected from the APD [7,8]. A more complete list can be searched in the APD.
For years, proline-rich peptides were proposed to act by binding to heat shock proteins [92].
Two papers published in 2014 challenged this view. Krizsan et al. found that insect-derived proline-rich
apidaecins and oncocins inhibited bacterial protein translation at the 70S ribosome [84]. Both cationic
and hydrophobic amino acids of the peptides were involved in such binding. Interestingly,
Mardirossian et al. also observed that Bac7(1-35), another proline-rich peptide corresponding to
N-terminal 35 residues of bovine cathelicidin Bac7, could accumulate within E. coli to a high
concentration of 340 µM and inhibits protein synthesis by targeting ribosomal proteins [85]. These
studies indicate that the well-documented chaperone DnaK is unlikely the major target for proline-rich
peptides. Of note, bacterial lasso peptides such as microcin J25 (MccJ25) can inhibit RNA
polymerase [83].
Some antimicrobial peptides can associate with DNA. In 2014, Ghosh et al. found that the WW motif
of indolicidin is essential for DNA binding. They provided high-resolution structural information for the
interaction of indolicidin with duplex DNA [93]. Such a structure can be useful for designing
novel antibiotics.
Interestingly, some bacteriocins use receptors as the target. While garvicin ML recognizes a maltose
ABC transporter, LsbB uses metallopeptidase as the targets [81]. In 2014, Kjos et al. found lactococcin
G and enterocin 1071 (two-chain bacteriocins) used UppP as the receptor. UppP is an enzyme involved
in cell wall synthesis [80]. Such findings not only enrich our view on the mechanisms of action of
antimicrobial peptides, but also open new opportunities for antimicrobial development.
Although it is likely that some antimicrobial peptides mainly utilize one mechanism to inhibit
bacteria, a single peptide may also deploy multiple mechanisms, rendering it difficult for pathogens to
develop resistance. In 2014, Wenzel et al. illustrated this using a model arginine and tryptophan-rich
peptide RWRWRW-NH2 (C-terminal amidation) [94]. The peptide is primarily membrane targeting
(e.g., D and L-forms have same activity) and only a very small population can enter the bacterial cell.
As a new mechanism, the authors found that multiple surface proteins could be delocalized by the
peptide. While the replacement of cytochrome C hinders bacterial energy metabolism, delocalization of
MinD interferes with bacterial replication. Another surface protein, MurG, can also be delocalized,
leading to impaired bacterial cell wall synthesis. The authors proposed that such bacterial surface protein
delocalization by cationic antimicrobial peptides may be a general mechanism. Our own recent findings
may provide additional insight into this protein delocalization. Surface attachment is usually mediated
by a short amphipathic sequence, which weakly interacts with bacterial membranes [95]. In contrast,
cationic antimicrobial peptides are able to better interact with bacterial membranes since they have a
broader hydrophobic surface or higher membrane perturbation potential [96]. Such a membrane-binding
difference could be one of the fundamental reasons for surface proteins to be replaced by cationic
antimicrobial peptides. In addition, membrane binding of short amphipathic sequences requires anionic
lipids [95]. When short cationic peptides cause lipid domain formation [94,97,98], the migration of anionic
lipids toward cationic antimicrobial peptides could weaken the attachment of surface proteins to the
re-organized membranes, causing protein delocalization and loss of function as demonstrated by
Wenzel et al. [94].
A single peptide can also possess multiple functions and human cathelicidin LL-37 is a typical
example for this [99]. The observation that LL-37 can associate with DNA led to the idea that DNA
binding may be part of the bacterial killing mechanism as well. However, Mardirossian et al. showed
that only 5% of LL-37 inhibited protein synthesis [85]. In agreement, we did not observe a correlation
between peptide activity and DNA retardation (Lau, K.; Lushnikova, T.; Wang, G., unpublished results).
However, we did observe a correlation between membrane permeation and antimicrobial activity of
LL-37 fragments [100]. These results support the existing view that membrane permeation and
disruption by the helical region (residues 2-31) is the major mechanism via which LL-37 kills
bacteria [78,79,97]. It appears that nucleic acid binding plays a more important role in RNA delivery
into endosomes [101] and in stabilizing neutrophil extracellular traps to prevent DNA cleavage [102].
Moreover, human LL-37 can associate with cell receptors to trigger signal transduction [103,104].
Interestingly, LL-37 also modulates innate immunity by promoting macrophages to phagocyte
bacteria [105] or influencing neutrophil responses to influenza A virus [106]. In addition, overexpressed
LL-37, as an antigen, can be specifically recognized by CD4+ and/or CD8+ T cells in psoriasis [107].
It is clear that the multifunctional roles of human LL-37 are realized by its ability to recognize and
interact with different molecular targets and immune cells.
4.2. Resistance Genes for Pathogens and Survival Skills for Commensal Bacteria
It has been appreciated that bacteria have been co-evolving with host defense peptides [108].
Some have learned how to avoid the attack by cationic peptides. The major mechanism appears to alter
cell envelope charge and composition. In addition, an ATP-binding cassette (ABC) transporter coupled
with an adjacent two-component system (TCS) also constitutes a resistance module against antimicrobial
peptides [109,110]. Elucidation of the genetic basis of bacterial resistance may be helpful for the
design of more potent antibiotics. In the following sections, we highlight progress made in this direction
during 2014.
4.2.1. Gram-Positive Bacteria
One can identify the bacterial genes involved in peptide response by two methods: proteome analysis
or genome analysis. Using proteome analysis of bacitracin-treated and untreated cells, Gebhard et al.
identified an ABC transporter EF2050-2049 of Enterococcus faecalis that mediates resistance against
bacitracin [109]. To validate this, they transferred the resistance and regulatory pathway to B. subtilis,
leading to bacitracin resistance. Thus, the ABC transporter and the TCS are indeed required for resistance
to antimicrobial peptides. Nevertheless, a previous genomic analysis identified two such ABC
transporters [110], which were induced by bacitracin [109]. Based on these results, the authors proposed
a model for the bacitracin resistance network of E. faecalis. The presence of bacitracin is initially
detected by the EF2752-51 ABC transporter, which relays this signal to an adjacent TCS (EF0926-27).
Activation of the regulatory domain of the TCS leads to an increase in expression of the EF2050-49
ABC transporter that confers resistance to antimicrobial peptides. This two transporters and one TCS
network mechanism [109] differs from those single ABC transporter and TCS cases where the
transporter senses the peptide and relays this signal to the adjacent TCS that upregulates the same ABC
transporter for resistance [110].
The five-component system GraXSR-VraFG of S. aureus is well-established as the major sensing
and resistance system [111] that reduces the toxic effect of cationic antimicrobial peptides by
upregulating genes such as mprF and dltABCD. While MprF can put lysines on anionic phophatidylglycerols
(PGs), DltABCD can modify the cell wall by transferring of D-alanine into teichoic acids [108,112].
GraSR was found to regulate the dltABCD and mprF genes [113,114]. In 2014, a loop region of sensor
protein GraS was identified to recognize cationic peptides. Cheung et al. generated mutants of graS from
the MRSA strain MW2. Deletion of graS (ΔgraS strain) or its 9-amino acid extracellular loop region
(ΔEL strain) made the strain more susceptible to daptomycin, polymyxin B, human neutrophil defensin
1 (HNP-1), and RP-1 (a platelet factor 4 derived peptide that retains activity in blood). Meanwhile, these
mutants became less infectious in vivo in an endocarditis model. Interestingly, a synthetic trimeric loop
region EL mimic, i.e., (DYDFPIDSL)3, could protect the parental MW2 strain from killing by those
cationic peptides. These results suggest that the acidic residues in the extracellular loop region of GraS
can directly interact with cationic peptides for sensing and activation [115].
It has been elucidated that Group A Streptococcus responds to the human antimicrobial peptide
LL-37 by upregulating virulence factors controlled by the CsrRS system. In 2014, Velarde et al.
identified RI-10, the smallest LL-37 fragment required to bind to CsrRS using a series of synthetic
LL-37 fragments. RI-10 can directly bind to sensor kinase CsrS to activate the expression of virulence
factors [116]. The same peptide was previously found by us to have no antibacterial activity against
bacteria [97,98]. Since antimicrobial activity is not required for this recognition by kinase receptor, such
a response could occur in vivo at a very low level of LL-37, which is not high enough to kill the bacteria.
We propose that interfacial cationic residues R23 and K25, which are important for membrane
permeation and bacterial killing [100], are also important residues for interaction with the acidic amino
acids on the CsrS receptor.
4.2.2. Gram-Negative Bacteria
Different from Gram-positive bacteria, LPS is the major component in the outer membranes of
Gram-negative bacteria [66]. Modifications of bacterial LPS provide a general mechanism that confers
resistance to cationic antimicrobial peptides [117]. The 2014 research on the genetic basis of bacterial
resistance yielded additional support for this. First, pathogenic Vibrio cholerae strains can be >100-fold
more resistant to polymyxins by modifying LPS (i.e., glycylation). Henderson et al. confirmed AlmF as
an aminoacyl carrier protein, which is activated by the enzyme AlmE. Interestingly, these proteins in the
AlmEFG trio system function in a manner similar to nonribosomal peptide synthetases [118]. Second,
the resistance of human pathogen Neisseria gonorrhoeae results from phosphoethanolamine (PEA)
decoration of lipid A by transferase encoded by the lptA gene [119–121]. Kandler et al. found that
high-frequency mutation in a polynucleotide repeat of the lptA gene influences bacterial resistance.
An lptA mutant is highly susceptible to cationic peptides [122]. In addition, the PEA-modification of
lipid A has an immunostimulatory role during infection [123]. Third, in the case of the gastrointestinal
pathogen S. typhimurium, resistance genes involving both LPS defects and mutation in phoP were found
from a transposon library in 1992 [124]. The PhoPQ two-component system regulates peptide resistance,
bacterial lipid A remodeling, and intracellular survival within acidified phagosomes. In 2014, the PhoPQ
system was found to also regulate acidic glycerophospholipid content in the outer membrane [125].
These authors have recently summarized the resistance strategies of S. typhi [126,127].
In summary, both Gram-positive and Gram-negative bacteria are able to decorate their cellular
surfaces to make them less attractive to cationic antimicrobial peptides. Interestingly, a recent study
reveals that gut bacteria can use a similar mechanism by removing a phosphate group from LPS [128].
Here a resistant mechanism for “bad bugs” has become a survival strategy for “good bugs”. Therefore,
such surface decorations achieved by a different chemistry provide a general mechanism that enables
bacteria, for good or bad, to “work under an umbrella” to dodge the “bullets” of the host.
5. Potential Applications of Antimicrobial Peptides
5.1. Toward Therapeutic Uses
There is continued interest in developing therapeutic uses for antimicrobial peptides. Because of
molecular simplicity and easy synthesis, linear peptides have been extensively explored for favorable
properties. Here we highlight a structure-based design based on the human cathelicidin LL-37.
Wang identified a chymotrypsin-resistant template by screening an LL-37 peptide library [129]. This
template contains partial D-amino acids and has a novel amphipathic structure [130]. However, it is not
active against community-associated methicillin-resistant S. aureus (MRSA) USA300. Based on the 3D
structure, we enhanced anti-MRSA activity of the peptide by inserting a bulkier hydrophobic group into
the structural cavity. One of the peptide analogs, 17BIPHE2, not only eliminated MRSA, but also
recruited monocytes to the infection site [129]. In addition, other approaches were explored to make use
of LL-37 or hBD-2. Since cathelicidin can reverse intestinal fibrosis in models of colitis [131], this
peptide may be used to treat inflammatory bowel disease (IBD) by introducing cathelicidin-overexpressing
bacteria. Using an adenoviral vector to deliver the gene of hBD-2, Woo et al. found both viral inhibition
and clearance for experimental otitis media [132]. In 2014, LL-37-containing vector was electroporated
to promote skin wound healing [133]. In addition, 1,25-dihydroxyvitamin D3 (active form) was also
used to induce both LL-37 and hBD-2 production in keratinocytes from diabetic foot ulcers, promoting
wound healing [134]. UV light or sunlight may be an alternative since hydroxylation of vitamin D can
occur [135]. It is notable that traditional practice can also boost our immune systems. While yoga
stretching significantly increases human hBD-2 [136], green tea helps the production of lactoferrin in
saliva after exercise [137]. Although at the early stage, these positive results on antimicrobial peptides
imply that our traditional life styles can be helpful to keep us healthy.
Unlike linear peptides that can be rapidly degraded by proteases in hours, circular peptides have
inherent stability. This is because these peptides such as cyclotides comprise three conserved disulfide
bonds in addition to a peptide bond that connects the N- and C-termini. Consequently, there is great
interest in utilizing these natural templates to engineer useful therapeutics [138,139]. In 2014, Craik and
colleagues demonstrated the molecular grafting technology where a desired antigenic peptide was
inserted into an exposed loop region of kalata B1 [140]. This technology confers protease stability to the
sequence motif, which can otherwise be rapidly degraded when tested alone. MOG3, one out of the
seven peptides grafted to loop 5, was used to vaccinate mice and found to display in vivo efficacy in an
animal model of multiple sclerosis, an inflammatory disease of the central nervous system. Taken
together with previous examples [138,139], these authors proved the concept of segment grafting at
loops 5 and 6 of cyclotides. It appears that sequence composition rather than length determines whether
the grafted segment is tolerated without disrupting the protein fold. To obtain a sufficient amount of
material for research, cyclotides were initially isolated from plants [141]. Later, chemical synthesis was
established [142]. In 2014, two laboratories reported an alternative approach by using engineered sortase
A to make the circular molecule [143,144]. A more efficient synthesis will bring us one step closer to
practical use of these interesting templates.
5.2. Peptide Surface Coating
Immobilization of antimicrobial peptides (either covalently or adsorbed) onto solid supports extends
their capabilities as surface-active molecules. This direction of research aims at improving biomedical
devices, drug delivery systems, bio-sensor and detection, and so on. Recent advances in the field include
simplification of the chemistry for surface attachment, development of novel substrate-attaching
platforms, including nanomaterial for wider applications, product development with promising proof of
concepts and in vivo testing in animal models.
Of all the problems related to loss in efficiency of medically implantable medical devices is the
development of microbial biofilms. Peptide immobilization has been shown to reduce bacterial
colonization and biofilm formation. However, the major challenges that often hinder the immobilization
of antimicrobial peptides are the inefficiency of the conjugation chemistries and their inability to achieve
a sufficient surface concentration of peptides, along with the limited number of usable biomaterials.
A recent study by Lim et al. [145] demonstrated a simple dopamine based chemical reaction for the
functionalization of antimicrobial peptides onto a commonly used Silicon Foley catheter. Not only did
the catheter prototype reduce biofilm formation by common pathogens that caused a urinary tract
infection, it was also stable for 21 days. In addition, hLF1-11 immobilized onto titanium [146] has been
shown to possess excellent anti-biofilm properties. There have also been improvements in other chemical
platforms, including the development of thiolated self-assembled monolayer on a gold surface to which
small peptides, temporin-SHf, can be tethered, resulting in broad-spectrum activity [147].
To understand the possible influence of structure and dynamics on immobilized antimicrobial
peptides and to apply rational design, molecular dynamics simulation studies were carried out on
cecropin P1 immobilized on silane-EG4-maleimide self-assembled monolayers [148]. Other factors
governing immobilization reactions, such as spacer chain length, reactant concentration and energy
dependence, are demonstrated by Mishra et al. [149]. Additional coating strategies can be found in a
recent review [150]. Moving toward practical applications, a significant in vivo study is presented by
Dutta et al. [151]. Melimine immobilized eye lenses are not only cytotoxically safe but also possess
antibacterial activity after worn as tested in both rabbit and human. In addition, another peptide SESB2V
immobilized on titanium surfaces prevents perioperative corneal infection in a rabbit keratitis
model [152].
5.3. Nanoparticle-Based Drug Delivery Systems
Apart from the anti-biofilm and antibacterial functions, antimicrobial peptides tagged to nanoparticles
impart a site-specific targeting and delivery of drug molecules. It can be used in treating a variety of
diseases, including cancer. Currently, dermaseptin entrapped chitosan nanoparticles have been shown to
possess excellent antitumor activities [153]. Moving one step forward, dual targeting nanoparticles with
both blood−brain barrier (BBB) and blood−brain tumor barrier (BBTB) including glioma cell were
achieved by functionalizing lactoferrin to the surface of poly(ethylene glycol)−poly(lactic acid)
nanoparticles. Administration with tLyP-1, a tumor-homing peptide that mediates tissue penetration
through the neuropilin-1-dependent internalization pathway, resulted in deep penetration of the
nanoparticle into the glioma parenchyma [154]. It opens a new direction for administration of
antitumerogenic drugs with high penetration capability.
Additionally, glutamic acid substitution of basic residues in LL-37, melittin, and bombolitin V linked
to lipid nanoparticles could be used for endosomal escape and efficient gene delivery using intravenous
injections. These yield expression levels comparable to those obtained using Lipofectamine 2000 and
the probable mode of action resembles viruses [155]. Antimicrobial peptides have also been shown to
have superb drug releasing properties in PEG-PLGA microparticles [156]. The direct evidence is
presented by encapsulating LL-37 in PLGA nanoparticles by Chereddy et al. [157]. PLGA-LL-37
nanoparticles as a biodegradable drug delivery system were found to promote wound closure. It
functions due to the sustained release of both LL-37 and lactate, and induction of enhanced cell migration
without effects on the metabolism and proliferation of keratinocytes. Moreover, peptides as short as
dimer conjugated to naphthalene could be used as antimicrobial nanomaterials in eliminating biofilm
infections and for drug delivery [158].
5.4. Biosensors and Detection
Antimicrobial peptides can also serve as indicators and diagnostic agents. The approach is more cost
effective than standard PCR or antibody-based techniques. Detection of bacterial pathogens in a
microfluidic chip where antimicrobial peptides are immobilized via cysteine-gold interaction could
produce a rapid electrical detection with sufficient sensor signal that allows the detection of pathogens
(both Gram-negative and Gram-positive) at a density as low as 105 cfu/mL within 25 min [159]. While
another platform for the detection of only Gram-positive bacterial strains could reach 103 cfu/mL via
immobilizing class IIa bacteriocins [160]. In addition, specific detection of fungal C. albicans can also
be made by using peptide nucleic acid probes [161].
6. Perspectives
It is great news that acquired resistance did not become an issue after decade-long use of antimicrobial
peptides such as tyrothricin [162]. Such an observation is encouraging to the current effort in
development of antimicrobial peptides into novel therapeutic molecules [63]. From 2000 to 2014, about
100 new antimicrobial peptides were entered into the APD every year [26]. As of December 2014, there
were 2493 peptides in this database [7–9]. We anticipate that the important work on the isolation and
characterization of novel antimicrobial peptides from new organisms will continue. Scientifically, new
peptide sequences will improve our knowledge of natural antimicrobial peptides. As shown in Table 1,
the new members can refine the boundary parameters for natural antimicrobial peptides [9]. With the
identification of a sufficient number of representative peptide sequences, the APD database will more
accurately identify natural peptides most similar to the input sequence. It will facilitate the development
of new programs to better predict the likelihood of a new peptide to be antimicrobial. In addition, a
unique peptide may directly become a candidate lead for the development of novel antimicrobials to
meet the challenge of the antibiotic resistance problem. However, it is important to validate whether a
bacteriocin has any undesired virulent property that promotes infection [21].
The 2014 research also enabled us to connect the dots for known human antimicrobial peptides,
leading to an improved understanding of their functional roles in innate immunity. Surprisingly,
a different form of human cathelicidin peptide can be rapidly expressed by skin fat cells in response to
the S. aureus invasion, underscoring a direct defense role of human cathelicidin peptides [50]. It is
remarkable that a single LL-37 molecule can perform multiple functions by recognizing a variety of
molecular partners or receptors on immune cells. In 2014, pH-dependent oligomerization of LL-37 is
connected to the delivery of dsRNA into endosomes for subsequent interactions with TLR3 [64].
Although the details are to be elucidated, we propose that the terminal regions of LL-37 contain an
important molecular switch based on NMR data [63]. It is demonstrated that local conditions are
essential for a proper function of human antimicrobial peptides. While human HD-6, like hBD-1,
is active only after disruption of disulfide bonds under reduced conditions [43], many other defensins in
the folded form can directly recognize specific lipids in pathogen’s membranes [163,164]. During such
a molecular recognition process, the flexible residues in the loop regions of these small defense proteins
are found to be essential based on several structural studies [163–166].
The 2014 results further expanded our view on the mechanism of action of antimicrobial peptides
(summarized in Figure 1). While select antimicrobial peptides are known to inhibit cell wall synthesis,
many target bacterial membranes. Surface-binding peptides are shown to be able to replace weakly
attached membrane proteins, thereby interfering with bacterial physiology globally [94]. Beyond
membranes, bacteriocins can use cell receptors as a target [81]. It has been known for a while that
proline-rich peptides interact with heat shock proteins [92]. However, the molecular target has now
been traced to ribosomal proteins. The binding of proline-rich peptides leads to inhibition of protein
synthesis [84,85].
Although there are few examples, structure-based design has been demonstrated [129,140], leading
to antimicrobials or vaccines with desired properties. The overall goal of peptide engineering is to
establish or identify a proper peptide template with desired potency, stability, and cell selectivity.
In addition, one may also mimic nature’s wisdom. Based on the precursor protein construction,
one can design pro-peptide forms to minimize potential cytotoxicity and protease degradation. In 2014,
Forde et al. illustrated this strategy as a potential therapy for cystic fibrosis [167,168]. Nature has created
other strategies to circumvent rapid peptide degradation by forming a complex structure. For instance,
human LL-37 can oligomerize at physiological pH into nanoparticles to resist the action of proteases [63].
Likewise, LL-37 can bind to DNA to stabilize the entire NETs structure [169]. In 2014, Bachrach and
colleagues showed that human LL-37 could also be protected by actin, thereby maintaining its
antimicrobial activity in vivo [170,171]. There are also natural ways to reduce potential cytotoxicity of
antimicrobial peptides. In 2014, Svensson et al. discovered that peptide p33 expressed on the surface of
various cell types can reduce the potential cytotoxicity of human LL-37 [172]. Moreover, Hiemstra et al.
discovered the nanoparticle-like vesicles in the human urinary tract [173]. It is predictable that novel
functional modes of human innate immune peptides will continue to emerge. All these natural mechanisms
may hold the key to future therapeutics.
We anticipate continued efforts in the development of potential applications of antimicrobial peptides,
including peptide production methods. Peptide engineering, formulation, and delivery technologies may
further expand the horizon of antimicrobial peptides in benefiting human beings [174]. Such applications
can vary from medical surface cleaning, water quality monitoring and disinfection, sterile surface
materials, to new drugs for infectious diseases [175,176]. Antimicrobial peptides may be included in
existing detergent formulation and disinfectants to reduce bacterial biofilms on hospital surfaces [177].
Bovicin HC5 and nisin can be used to treat food-contact surface to reduce bacterial attachment and
subsequent biofilm formation [178,179]. It has been demonstrated that injection of an engineered LL-37
peptide or coating peptides to the device surface can prevent biofilm formation [129,145,146].
Importantly, a combined use of antimicrobial peptides with traditional antibiotics can be a more effective
strategy to treat bacterial biofilms [180–182]. Finally, molecules that interfere with or even weaken the
process of biofilm formation [183–189] can also be combined with antimicrobial peptides to achieve an
optimal treatment of bacterial biofilms.
Acknowledgements
This study is supported by the grants from the NIAID/NIH R01AI105147 and the state of Nebraska
to GW. We thank Cheryl Putnam for final editing.
Author Contributions
GW conceived the project. GW and BM drafted the manuscript. All authors were involved in
literature search, discussion and writing.
Conflicts of Interest
No conflicts of interest was declared.
References
1. Zasloff, M. Antimicrobial peptides of multicellullar organisms. Nature 2002, 415, 359–365.

2. Lai, Y.; Gallo, R.L. AMPed up immunity: How antimicrobial peptides have multiple roles in
immune defense. Trends Immunol. 2009, 30, 131–141.
3. Hancock, R.E.; Lehrer, R. Cationic peptides: A new source of antibiotics. Trends Biotechnol. 1998,
16, 82–88.
4. Yeaman, M.R.; Yount, N.Y. Mechanisms of Antimicrobial Peptide Action and Resistance.
Pharmacol. Rev. 2003, 55, 27–55.
5. Brogden, K.A. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Natl. Rev.
Microbiol. 2005, 3, 238–250.
6. NCBI Resource Coordinators. Database resources of the National Center for Biotechnology
Information. Nucleic Acids Res. 2015, 43, D6–D17.
7. Wang, Z.; Wang, G. APD: The antimicrobial peptide database. Nucleic Acids Res. 2004, 32,
D590–D592.
8. Wang, G.; Li, X.; Wang, Z. The updated antimicrobial peptide database and its application in
peptide design. Nucleic Acids Res. 2009, 37, D933–D937.
9. Wang, G. Improved methods for classification, prediction, and design of antimicrobial peptides.
Methods Mol. Biol. 2015, 1268, 43–66.
10. Timeline of Antimicrobial Peptide Discovery. http://aps.unmc.edu/AP/timeline.php. Accessed on
16 March 2015.
11. Chakchouk-Mtibaa, A.; Elleuch, L.; Smaoui, S.; Najah, S.; Sellem, I.; Abdelkafi, S.; Mellouli, L.
An antilisterial bacteriocin BacFL31 produced by Enterococcus faecium FL31 with a novel
structure containing hydroxyproline residues. Anaerobe 2014, 27C, 1–6.
12. Niggemann, J.; Bozko, P.; Bruns, N.; Wodtke, A.; Gieseler, M.T.; Thomas, K.; Jahns, C.; Nimtz, M.;
Reupke, I.; Brüser, T.; et al. Baceridin, a cyclic hexapeptide from an epiphytic Bacillus strain,
inhibits the proteasome. Chembiochem 2014, 15, 1021–1029.
13. Gavrish, E.; Sit, C.S.; Cao, S.; Kandror, O.; Spoering, A.; Peoples, A.; Ling, L.; Fetterman, A.;
Hughes, D.; Bissell, A.; et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills
mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem. Biol.
2014, 21, 509–518.
14. Yamanaka, K.; Reynolds, K.A.; Kersten, R.D.; Ryan, K.S.; Gonzalez, D.J.; Nizet, V.; Dorrestein,
P.C.; Moore, B.S. Direct cloning and refactoring of a silent lipopeptide biosynthetic gene cluster
yields the antibiotic taromycin A. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 1957–1962.
15. Scholz, R.; Vater, J.; Budiharjo, A.; Wang, Z.; He, Y.; Dietel, K.; Schwecke, T.; Herfort, S.;
Lasch, P.; Borriss, R. Amylocyclicin, a Novel Circular Bacteriocin Produced by Bacillus
amyloliquefaciens FZB42. J. Bacteriol. 2014, 196, 1842–1852.
16. Tang, Y.Q.; Yuan, J.; Osapay, G.; Osapay, K.; Tran, D.; Miller, C.J.; Ouellette, A.J.; Selsted, M.E.
A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated
alpha-defensins. Science 1999, 286, 498–502.
17. Falcao, C.B.; de La Torre, B.G.; Pérez-Peinado, C.; Barron, A.E.; Andreu, D.; Rádis-Baptista, G.
Vipericidins: a novel family of cathelicidin-related peptides from the venom gland of South
American pit vipers. Amino Acids 2014, 46, 2561–2571.
18. Conlon, J.M.; Mechkarska, M. Host-defense peptides with therapeutic potential from skin
secretions of frogs from the family pipidae. Pharmaceuticals 2014, 7, 58–77.
19. Guo, C.; Hu, Y.; Li, J.; Liu, Y.; Li, S.; Yan, K.; Wang, X.; Liu, J.; Wang, H. Identification of
multiple peptides with antioxidant and antimicrobial activities from skin and its secretions of
Hylarana taipehensis, Amolops lifanensis, and Amolops granulosus. Biochimie. 2014, 105,
192–201.
20. Ryazantsev, D.Y.; Rogozhin, E.A.; Dimitrieva, T.V.; Drobyazina, P.E.; Khadeeva, N.V.;
Egorov, T.A.; Grishin, E.V.; Zavriev, S.K. A novel hairpin-like antimicrobial peptide from
barnyard grass (Echinochloa crusgalli L.) seeds: Structure-functional and molecular-genetics
characterization. Biochimie 2014, 99, 63–70.
21. Li, M.F.; Zhang, B.C.; Li, J.; Sun, L. Sil: A Streptococcus iniae bacteriocin with dual role as an
antimicrobial and an immunomodulator that inhibits innate immune response and promotes S.
iniae infection. PLoS One. 2014, 9, e96222.
22. Weisshoff, H.; Hentschel, S.; Zaspel, I.; Jarling, R.; Krause, E.; Pham, T.L. PPZPMs—A novel
group of cyclic lipodepsipeptides produced by the Phytophthora alni associated strain
Pseudomonas sp. JX090307—The missing link between the viscosin and amphisin group.
Nat. Prod. Commun. 2014, 9, 989–996.
23. Trindade, F.; Amado, F.; Pinto da Costa, J.; Ferreira, R.; Maia, C.; Henriques, I.; Colaco, B.;
Vitorino, R. Salivary peptidomic as a tool to disclose new potential antimicrobial peptides.
J. Proteomics 2014, 115C, 49–57.
24. Bouzid, W.; Verdenaud, M.; Klopp, C.; Ducancel, F.; Noirot, C.; Vetillard, A. de novo sequencing
and transcriptome analysis for tetramorium bicarinatum: A comprehensive venom gland
transcriptome analysis from an ant species. BMC Genomics 2014, 15, 987.
25. Capriotti, A.L.; Cavaliere, C.; Foglia, P.; Piovesana, S.; Samperi, R.; Zenezini Chiozzi, R.;
Lagana, A. Development of an analytical strategy for the identification of potential bioactive
peptides generated by in vitro tryptic digestion of fish muscle proteins. Anal. Bioanal. Chem. 2015,
407, 845–854.
26. Wang, G. Database-guided discovery of potent peptides to combat HIV-1 or superbugs.
Pharmaceuticals 2013, 6, 728–758.
27. Tareq, F.S.; Lee, M.A.; Lee, H.S.; Lee, Y.J.; Lee, J.S.; Hasan, C.M.; Islam, M.T.; Shin, H.J.
Gageotetrins A-C, Noncytotoxic antimicrobial linear lipopeptides from a marine bacterium
Bacillus subtilis. Org. Lett. 2014, 16, 928–931.
28. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides. Proc.
Natl. Acad. Sci. U.S.A. 2006, 103, 15997–16002.
29. First in a New Class of Antibiotics. FDA Consum. 2003, 37, 4.
30. Chopra, L.; Singh, G.; Choudhary, V.; Sahoo, D.K. Sonorensin: an antimicrobial peptide,
belonging to the heterocycloanthracin subfamily of bacteriocins, from a new marine isolate,
Bacillus sonorensis MT93. Appl. Environ. Microbiol. 2014, 80, 2981–2990.
31. Mygind, P.H.; Fischer, R.L.; Schnorr, K.M.; Hansen, M.T.; Sonksen, C.P.; Ludvigsen, S.;
Raventos, D.; Buskov, S.; Christensen, B.; De Maria, L.; et al. Plectasin is a peptide antibiotic with
therapeutic potential from a saprophytic fungus. Nature 2005, 437, 975–980.
32. Oeemig, J.S.; Lynggaard, C.; Knudsen, D.H.; Hansen, F.T.; Norgaard, K.D.; Schneider, T.;
Vad, B.S.; Sandvang, D.H.; Nielsen, L.A.; Neve, S.; et al. Eurocin, a new fungal defensin:
structure, lipid binding, and its mode of action. J. Biol. Chem. 2012, 287, 42361–42372.
33. Essig, A.; Hofmann, D.; Munch, D.; Gayathri, S.; Kunzler, M.; Kallio, P.T.; Sahl, H.G.;
Wider, G.; Schneider, T.; Aebi, M. Copsin, a novel peptide-based fungal antibiotic interfering with
the peptidoglycan synthesis. J. Biol. Chem. 2014, 289, 34953–34964.
34. Sharma, S.; Verma, H.N.; Sharma, N.K. Cationic bioactive peptide from the seeds of Benincasa
hispida. Int. J. Pept. 2014, 2014, 156060.
35. Kawabata, S.; Nagayama, R.; Hirata, M.; Shigenaga, T.; Agarwala, K.L.; Saito, T.; Cho, J.;
Nakajima, H.; Takagi, T.; Iwanaga, S. Tachycitin, a small granular component in horseshoe crab
hemocytes, is an antimicrobial protein with chitin-binding activity. J. Biochem. 1996, 120,
1253–1260.
36. Conlon, J.M.; Mechkarska, M.; Emanahmed Coquet, L.; Jouenne, T.; Jérômeleprince Vaudry, H.;
Hayes, M.P; Padgett-Flohr, G. Host defense peptides in skin secretions of the Oregon spotted frog
Ranapretiosa: Implications for species resistance to chytridiomycosis. Dev. Comp. Immunol. 2011,
35, 644–649.
37. Thomas, S.; Karnik, S.; Barai, R.S.; Jayaraman, V.K.; Idicula-Thomas, S. CAMP: A useful
resource for research on antimicrobial peptides. Nucleic Acids Res. 2010, 38, D774–D780.
38. Lata, S.; Mishra, N.K.; Raghava, G.P. AntiBP2: Improved version of antibacterial peptide
prediction. BMC Bioinformatics 2010, 11, S19.
39. Xiao, X.; Wang, P.; Lin, W.Z.; Jia, J.H.; Chou, K.C. iAMP-2L: A two-level multi-label classifier
for identifying antimicrobial peptides and their functional types. Anal. Biochem. 2013, 436,
168–177.
40. Zanetti, M. the role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol.
Biol. 2005, 7, 179–196.
41. Hao, X.; Yang, H.; Wei, L.; Yang, S.; Zhu, W.; Ma, D.; Yu, H.; Lai, R. Amphibian cathelicidin
fills the evolutionary gap of cathelicidin in vertebrate. Amino acids 2012, 43, 677–685.
42. Ling, G.; Gao, J.; Zhang, S.; Xie, Z.; Wei, L.; Yu, H.; Wang, Y. Cathelicidins from the bullfrog
Rana catesbeiana provides novel template for peptide antibiotic design. PLoS One 2014, 9, e93216.
43. Schroeder, B.O.; Ehmann, D.; Precht, J.C.; Castillo, P.A.; Kuchler, R.; Berger, J.; Schaller, M.;
Stange, E.F.; Wehkamp, J. Paneth Cell Alpha-defensin 6 (HD-6) is an antimicrobial peptide.
Mucosal Immunol. 2014. doi: 10.1038/mi.2014.100.
44. Liu, H.; Yu, H.; Xin, A.; Shi, H.; Gu, Y.; Zhang, Y.; Diao, H.; Lin, D. Production and
characterization of recombinant human beta-defensin DEFB120. J. Pept. Sci. 2014, 20, 251–257.
45. Gela, A.; Kasetty, G.; Jovic, S.; Ekoff, M.; Nilsson, G.; Morgelin, M.; Kjellstrom, S.; Pease, J.E.;
Schmidtchen, A.; Egesten, A. Eotaxin-3 (CCL26) Exerts innate host defense activities that are
modulated by mast cell proteases. Allergy 2015, 70, 161–170.
46. Becknell, B.; Eichler, T.E.; Beceiro, S.; Li, B.; Easterling, R.S.; Carpenter, A.R.; James, C.L.;
McHugh, K.M.; Hains, D.S.; Partida-Sanchez, S. et al. Ribonucleases 6 and 7 have antimicrobial
function in the human and murine urinary tract. Kidney Int. 2015, 87, 151–161.
47. Wang, G. Human antimicrobial peptides and proteins. Pharmaceuticals 2014, 7, 545–594.
48. Boman, H.G. Antibacterial peptides: Basic facts and emerging concepts. J. Inter. Med. 2003, 254,
197–215.
49. Gschwandtner, M.; Zhong, S.; Tschachler, A.; Mlitz, V.; Karner, S.; Elbe-Bürger, A.;
Mildner, M. Fetal human keratinocytes produce large amounts of antimicrobial peptides:
Involvement of histone-methylation processes. J. Invest Dermatol. 2014, 134, 2192–2201.
50. Zhang, L,J,; Guerrero-Juarez, C.F.; Hata, T.; Bapat, S.P.; Ramos, R.; Plikus, M.V.; Gallo, R.L.
Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin
infection. Science 2015, 347, 67–71.
51. Lee, P.H.; Ohtake, T.; Zaiou, M.; Murakami, M.; Rudisill, J.A.; Lin, K.H.; Gallo, R.L. Expression
of an additional cathelicidin antimicrobial peptide protects against bacterial skin infection.
Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3750–3755.
52. Zhao, C.; Wang, I.; Lehrer, R.I. Widespread expression of beta-defensin hBD-1 in human
secretory glands and epithelial cells. FEBS Lett. 1996, 396, 319–322.
53. Furci, L.; Baldan, R.; Bianchini, V.; Trovato, A.; Ossi, C.; Cichero, P.; Cirillo, D.M. A new role
for human alpha-defensin 5 in the fight against Clostridium difficile hypervirulent strains.
Infect. Immun. 2015, 83, 986–995.
54. Hubert, P.; Herman, L.; Roncarati, P.; Maillard, C.; Renoux, V.; Demoulin, S.; Erpicum, C.;
Foidart, J.M.; Boniver, J.; Noel, A. et al. Altered alpha-defensin 5 expression in cervical
squamocolumnar junction: implication in the formation of a viral/tumour-permissive
microenvironment. J. Pathol. 2014, 234, 464–477.
55. Wiens, M.E.; Smith, J.G. Alpha-Defensin HD5 Inhibits Furin Cleavage of HPV16 L2 to Block
Infection. J. Virol. 2014, 89, 2866–2874.
56. Wommack, A.J.; Ziarek, J.J.; Tomaras, J.; Chileveru, H.R.; Zhang, Y.; Wagner, G.; Nolan, E.M.
Discovery and characterization of a disulfide-locked C(2)-symmetric defensin peptide. J. Am.
Chem. Soc. 2014, 136, 13494–13497.
57. Schroeder, B.O.; Wu, Z.; Nuding, S.; Groscurth, S.; Marcinowski, M.; Beisner, J.; Buchner, J.;
Schaller, M.; Stange, E.F.; Wehkamp, J. Reduction of disulphide bonds unmasks potent
antimicrobial activity of human beta-defensin 1. Nature 2011, 469, 419–423.
58. Porter, E.M.; Poles, M.A.; Lee, J.S.; Naitoh, J; Bevins, C.L.; Ganz, T. Isolation of human intestinal
defensins from ileal neobladder urine. FEBS Lett. 1998, 434, 272–276.
59. Chu, H.; Pazgier, M.; Jung, G.; Nuccio, S.P.; Castillo, P.A.; de Jong, M.F.; Winter, M.G.;
Winter, S.E.; Wehkamp, J.; Shen, B.; et al. Human Alpha-Defensin 6 Promotes mucosal innate
immunity through self-assembled peptide nanonets. Science 2012, 337, 477–481.
60. Abou Alaiwa, M.H.; Reznikov, L.R.; Gansemer, N.D.; Sheets, K.A.; Horswill, A.R.; Stoltz, D.A.;
Zabner, J.; Welsh, M.J. PH Modulates the activity and synergism of the airway surface liquid
antimicrobials beta-defensin-3 and LL-37. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, 18703–18708.
61. Johansson, J.; Gudmundsson, G.H.; Rottenberg, M.E.; Berndt, K.D.; Agerberth, B. Conformation-
dependent antibacterial activity of the naturally occurring human peptide LL-37. J. Biol. Chem.
1998, 273, 3718–3724.
62. Xhindoli, D.; Pacor, S.; Guida, F.; Antcheva, N.; Tossi, A. Native oligomerization determines the
mode of action and biological activities of human cathelicidin LL-37. Biochem. J. 2014, 457,
263–275.
63. Wang, G. Antimicrobial Peptides: Discovery, Design and Novel Therapeutic Strategies; CABI:
Wallingford, UK, 2010.
64. Singh, D.; Vaughan, R.; Kao, C.C. LL-37 peptide enhancement of signal transduction by toll-like
receptor 3 is regulated by pH: identification of a peptide antagonist of LL-37. J. Biol. Chem. 2014,
289, 27614–27624.
65. Yamasaki, K.; Schauber, J.; Coda, A.; Lin, H.; Dorschner, R.A.; Schechter, N.M.; Bonnart, C.;
Descargues, P.; Hovnanian, A.; Gallo, R.L. Kallikrein-mediated proteolysis regulates the antimicrobial
effects of cathelicidins in skin. FASEB J. 2006, 20, 2068–2080.
66. Wang, G.; Mishra, B.; Epand, R.F.; Epand, R.M. High-quality 3D structures shine light on
antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.
Biochim. Biophys. Acta 2014, 1838, 2160–2172.
67. Koziel, J.; Bryzek, D.; Sroka, A.; Maresz, K.; Glowczyk, I.; Bielecka, E.; Kantyka, T.; Pyrc, K.;
Svoboda, P.; Pohl, J.; et al. Citrullination alters immunomodulatory function of ll-37 essential for
prevention of endotoxin-induced sepsis. J. Immunol. 2014, 192, 5363–5372.
68. Picchianti, M.; Russo, C.; Castagnini, M.; Biagini, M.; Soldaini, E.; Balducci, E. NAD-Dependent
ADP-ribosylation of the human antimicrobial and immune-modulatory peptide LL-37 by
ADP-ribosyltransferase-1. Innate Immun. 2015, 21, 314–321.
69. Sørensen, O.E.; Gram, L.; Johnsen, A.H.; Andersson, E.; Bangsbøll, S.; Tjabringa, G.S.;
Hiemstra, P.S.; Malm, J.; Egesten, A.; Borregaard, N. Processing of seminal plasma hCAP-18 to
ALL-38 by gastricsin: A novel mechanism of generating antimicrobial peptides in vagina. J. Biol.
Chem. 2003, 278, 28540–28546.
70. Nguyen, L.T.; Haney, E.F.; Vogel, H.J. The expanding scope of antimicrobial peptide structures
and their modes of action. Trends Biotechnol. 2011, 29, 464–472.
71. Gazit, E.; Miller, I.R.; Biggin, P.C.; Sansom, M.S.; Shai, Y. Structure and orientation of the
mammalian antibacterial peptide cecropin p1 within phospholipid membranes. J. Mol. Biol. 1996,
258, 860–870.
72. Perrin, B.S., Jr; Tian, Y.; Fu, R.; Grant, C.V.; Chekmenev, E.Y.; Wieczorek, W.E.; Dao, A.E.;
Hayden, R.M.; Burzynski, C.M.; Venable, R.M.; et al. High-resolution structures and orientations
of antimicrobial peptides piscidin 1 and piscidin 3 in fluid bilayers reveal tilting, kinking, and
bilayer immersion. J. Am. Chem. Soc. 2014, 136, 3491–3504.
73. Fox, R.O., Jr.; Richards, F.M. A voltage-gated ion channel model inferred from the crystal
structure of alamethicin at 1.5-Å resolution. Nature 1982, 300, 325–330.
74. Kovacs, F.; Quine, J.; Cross, T.A. Validation of the single-stranded channel conformation of
gramicidin A by solid-state NMR. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7910–7915.
75. Burian, M.; Schittek, B. The secrets of dermcidin action. Int. J. Med. Microbiol. 2015, 305,
283–286.
76. Song, C.; Weichbrodt, C.; Salnikov, E.S.; Dynowski, M.; Forsberg, B.O.; Bechinger, B.; Steinem, C.;
de Groot, B.L.; Zachariae, U.; Zeth, K. Crystal structure and functional mechanism of a human
antimicrobial membrane channel. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 4586–4591.
77. Mukherjee, S.; Zheng, H.; Derebe, M.G.; Callenberg, K.M.; Partch, C.L.; Rollins, D.;
Propheter, D.C.; Rizo, J.; Grabe, M.; Jiang, Q.X.; et al. Antibacterial membrane attack by a pore-
forming intestinal c-type lectin. Nature 2014, 505, 103–107.
78. Henzler Wildman, K.A.; Lee, D.K.; Ramamoorthy, A. Mechanism of lipid bilayer disruption by
the human antimicrobial peptide, LL-37. Biochemistry 2003, 42, 6545–6558.
79. Oren, Z.; Lerman, J.C.; Gudmundsson, G.H.; Agerberth, B.; Shai, Y. Structure and organization
of the human antimicrobial peptide LL-37 in phospholipid membranes: Relevance to the molecular
basis for its non-cell-selective activity. Biochem. J. 1999, 341(Pt 3), 501–513.
80. Kjos, M.; Oppegard, C.; Diep, D.B.; Nes, I.F.; Veening, J.W.; Nissen-Meyer, J.; Kristensen, T.
Sensitivity to the two-peptide bacteriocin lactococcin G is dependent on UppP, an enzyme
involved in cell-wall synthesis. Mol. Microbiol. 2014, 92, 1177–1187.
81. Cotter, P.D. An 'Upp'-turn in bacteriocin receptor identification. Mol. Microbiol. 2014, 92,
1159–1163.
82. Wilmes, M.; Stockem, M.; Bierbaum, G.; Schlag, M.; Gotz, F.; Tran, D.Q.; Schaal, J.B.;
Ouellette, A.J.; Selsted, M.E.; Sahl, H.G. Killing of staphylococci by theta-defensins involves
membrane impairment and activation of autolytic enzymes. Antibiotics (Basel) 2014, 3, 617–631.
83. Mukhopadhyay, J.; Sineva, E.; Knight, J.; Levy, R.M.; Ebright, R.H. Antibacterial peptide
microcin J25 inhibits transcription by binding within and obstructing the RNA polymerase
secondary channel. Mol. Cell 2004, 14, 739–751.
84. Krizsan, A.; Volke, D.; Weinert, S.; Strater, N.; Knappe, D.; Hoffmann, R. Insect-derived proline-
rich antimicrobial peptides kill bacteria by inhibiting bacterial protein translation at the 70S
ribosome. Angew. Chem. Int. Ed. Engl. 2014, 53, 12236–12239.
85. Mardirossian, M.; Grzela, R.; Giglione, C.; Meinnel, T.; Gennaro, R.; Mergaert, P.; Scocchi, M.
The Host antimicrobial peptide Bac7(1–35) binds to bacterial ribosomal proteins and inhibits
protein synthesis. Chem. Biol. 2014, 21, 1639–1647.
86. De Leeuw, E.; Li, C.; Zeng, P.; Li, C.; Diepeveen-de Buin, M.; Lu, W.Y.; Breukink, E.; Lu, W.
Functional interaction of human neutrophil peptide-1 with the cell wall precursor lipid II.
FEBS Lett. 2010, 584, 1543–1548.
87. Sass, V.; Schneider, T.; Wilmes, M.; Körner, C.; Tossi, A.; Novikova, N.; Shamova, O.; Sahl,
H.G. Human beta-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect. Immun. 2010,
78, 2793–2800.
88. Bierbaum, G.; Sahl, H.G. Lantibiotics: Mode of action, biosynthesis and bioengineering.
Curr. Pharm. Biotechnol. 2009, 10, 2–18.
89. Iwamoto, K.; Hayakawa, T.; Murate, M.; Makino, A.; Ito, K.; Fujisawa, T.; Kobayashi, T.
Curvature-dependent recognition of ethanolamine phospholipids by duramycin and cinnamycin.
Biophys. J. 2007, 93, 1608–1619.
90. Henriques, S.T.; Huang, Y.H.; Castanho, M.A.; Bagatolli, L.A.; Sonza, S.; Tachedjian, G.;
Daly, N.L.; Craik, D.J. phosphatidylethanolamine binding is a conserved feature of cyclotide-
membrane interactions. J. Biol. Chem. 2012, 287, 33629–33643.
91. Troeira Henriques, S.; Huang, Y.H.; Chaousis, S.; Wang, C.K.; Craik, D.J. anticancer and toxic
properties of cyclotides are dependent on phosphatidylethanolamine phospholipid targeting.
Chembiochem 2014, 15, 1956–1965.
92. Otvos, L., Jr; Insug, O.; Rogers, M.E.; Consolvo, P.J.; Condie, B.A.; Lovas, S.; Bulet, P.;
Blaszczyk-Thurin, M. Interaction between heat shock proteins and antimicrobial peptides.
Biochemistry 2000, 39, 14150–14159.
93. Ghosh, A.; Kar, R.K.; Jana, J.; Saha, A.; Jana, B.; Krishnamoorthy, J.; Kumar, D.; Ghosh, S.;
Chatterjee, S.; Bhunia, A. Indolicidin targets duplex DNA: Structural and mechanistic insight
through a combination of spectroscopy and microscopy. ChemMedChem 2014, 9, 2052–2058.
94. Wenzel, M.; Chiriac, A.I.; Otto, A.; Zweytick, D.; May, C.; Schumacher, C.; Gust, R.; Albada, H.B.;
Penkova, M.; Kramer, U.; et al. Small cationic antimicrobial peptides delocalize peripheral
membrane proteins. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E1409–E1418.
95. Wang, G.; Peterkofsky, A.; Clore, G.M. A novel membrane anchor function for the N-terminal
amphipathic sequence of the signal-transducing protein IIAglucose of the Escherichia coli
phosphotransferase system. J. Biol. Chem. 2000, 275, 39811–39814.
96. Wang, G.; Li, Y.; Li, X. Correlation of three-dimensional structures with the antibacterial activity
of a group of peptides designed based on a nontoxic bacterial membrane anchor. J. Biol. Chem.
2005, 280, 5803–5811.
97. Wang, G. Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial
peptide KR-12 in lipid micelles. J. Biol. Chem. 2008, 283, 32637–32643.
98. Epand, RF; Wang, G.; Berno, B.; Epand, R.M. Lipid segregation explains selective toxicity of a
series of fragments derived from the human cathelicidin LL-37. Antimicrob. Agents Chemother.
2009, 53, 3705–3714.
99. Bals, R.; Wilson, J.M. Cathelicidins—A family of multifunctional antimicrobial peptides. Cell.
Mol. Life Sci. 2003, 60, 711–720.
100. Wang, G.; Epand, R.F.; Mishra, B.; Lushnikova, T.; Thomas, V.C.; Bayles, K.W.; Epand, R.M.
Decoding the functional roles of cationic side chains of the major antimicrobial region of human
cathelicidin LL-37. Antimicrob. Agents Chemother. 2012, 56, 845–856.
101. Nakagawa, Y.; Gallo, R.L. Endogenous intracellular cathelicidin enhances TLR9 activation in
dendritic cells and macrophages. J. Immunol. 2015, 194, 1274–1284.
102. Neumann, A.; Berends, E.T.; Nerlich, A.; Molhoek, E.M.; Gallo, R.L.; Meerloo, T.; Nizet, V.;
Naim, H.Y.; von Kockritz-Blickwede, M. The antimicrobial peptide LL-37 facilitates the
formation of neutrophil extracellular traps. Biochem. J. 2014, 464, 3–11.
103. Yang, D.; Chen, Q.; Schmidt, A.P.; Anderson, G.M.; Wang, J.M.; Wooters, J.; Oppenheim, J.J.;
Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl
peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils,
monocytes, and T cells. J. Exp. Med. 2000, 192, 1069–1074.
104. Elssner, A.; Duncan, M.; Gavrilin, M.; Wewers, M.D. A novel P2X7 receptor activator, the human
cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 2004,
172, 4987–4994.
105. Wan, M.; van der Does, A.M.; Tang, X.; Lindbom, L.; Agerberth, B.; Haeggstrom, J.Z.
Antimicrobial peptide LL-37 promotes bacterial phagocytosis by human macrophages. J. Leukoc.
Biol. 2014, 95, 971–981.
106. Tripathi, S.; Verma, A.; Kim, E.J.; White, M.R.; Hartshorn, K.L. LL-37 modulates human
neutrophil responses to influenza a virus. J. Leukoc. Biol. 2014, 96, 931–938.
107. Lande, R.; Botti, E.; Jandus, C.; Dojcinovic, D.; Fanelli, G.; Conrad, C.; Chamilos, G.; Feldmeyer, L.;
Marinari, B.; Chon, S.; et al. The antimicrobial peptide LL37 is a T-Cell autoantigen in psoriasis.
Nat. Commun. 2014, 5, 5621.
108. Peschel, A. How do bacteria resist human antimicrobial peptides? Trends Microbiol. 2002, 10,
179–186.
109. Gebhard, S.; Fang, C.; Shaaly, A.; Leslie, D.J.; Weimar, M.R.; Kalamorz, F.; Carne, A.;
Cook, G.M. Identification and characterization of a bacitracin resistance network in Enterococcus
faecalis. Antimicrob. Agents Chemother. 2014, 58, 1425–1433.
110. Dintner, S.; Staron, A.; Berchtold, E.; Petri, T.; Mascher, T.; Gebhard, S. Coevolution of ABC
transporters and two-component regulatory systems as resistance modules against antimicrobial
peptides in Firmicutes Bacteria. J. Bacteriol. 2011, 193, 3851–3862.
111. Falord, M.; Karimova, G.; Hiron, A.; Msadek, T. GraXSR proteins interact with the VraFG ABC
transporter to form a five-component system required for cationic antimicrobial peptide sensing
and resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 2012, 56, 1047–1058.
112. Weidenmaier, C.; Peschel, A.; Kempf, V.A.; Lucindo, N.; Yeaman, M.R.; Bayer, A.S. DltABCD-
and mprF-mediated cell envelope modifications of Staphylococcus aureus confer resistance to
platelet microbicidal proteins and contribute to virulence in a rabbit endocarditis model. Infect.
Immun. 2005, 73, 8033–8038.
113. Li, M; Cha, D.J.; Lai, Y.; Villaruz, A.E.; Sturdevant, D.E.; Otto, M. The antimicrobial peptide-
sensing system aps of Staphylococcus aureus. Mol. Microbiol. 2007, 66, 1136–1147.
114. Yang, S.-J.; Bayer, A.S.; Mishra, N.N.; Meehl, M.; Ledala, N.; Yeaman, M.R.; Xiong, Y.Q.;
Cheung, A.L. The Staphylococcus aureus two-component regulatory system, GraRS, senses and
confers resistance to selected cationic antimicrobial peptides. Infect. Immun. 2012, 80, 74–81.
115. Cheung, A.L.; Bayer, A.S.; Yeaman, M.R.; Xiong, Y.Q.; Waring, A.J.; Memmi, G.;
Donegan, N.; Chaili, S.; Yang, S.J. Site-specific mutation of the sensor kinase GraS in
Staphylococcus aureus alters the adaptive response to distinct cationic antimicrobial peptides.
Infect. Immun. 2014, 82, 5336–5345.
116. Velarde, J.J.; Ashbaugh, M.; Wessels, M.R. The human antimicrobial peptide LL-37 binds directly
to CsrS, a sensor histidine kinase of group A Streptococcus, to activate expression of virulence
factors. J. Biol. Chem. 2014, 289, 36315–36324.
117. Chen, H.D.; Groisman, E.A. The biology of the PmrA/PmrB two-component system: The major
regulator of lipopolysaccharide modifications. Annu. Rev. Microbiol. 2013, 67, 83–112.
118. Henderson, J.C.; Fage, C.D.; Cannon, J.R.; Brodbelt, J.S.; Keatinge-Clay, A.T.; Trent, M.S.
Antimicrobial peptide resistance of Vibrio cholerae results from an lps modification pathway
related to nonribosomal peptide synthetases. ACS Chem. Biol. 2014, 9, 2382–2392.
119. Tzeng, Y.L.; Ambrose, K.D.; Zughaier, S.; Zhou, X.; Miller, Y.K.; Shafer, W.M.; Stephens, D.S.
Cationic antimicrobial peptide resistance in Neisseria meningitidis. J. Bacteriol. 2005, 187,
5387–5396.
120. Balthazar, J.T.; Gusa, A.; Martin, L.E.; Choudhury, B.; Carlson, R.; Shafer, W.M. Lipooligosaccharide
structure is an important determinant in the resistance of Neisseria gonorrhoeae to antimicrobial
agents of innate host defense. Front. Microbiol. 2011, 2, 30.
121. Handing, J.W.; Criss, A.K. The lipooligosaccharide-modifying enzyme LptA enhances
gonococcal defence against human neutrophils. Cell. Microbiol. 2014, doi: 10.1111/cmi.12411.
122. Kandler, J.L.; Joseph, S.J.; Balthazar, J.T.; Dhulipala, V.; Read, T.D.; Jerse, A.E.; Shafer, W.M.
Phase-variable expression of lpta modulates the resistance of Neisseria gonorrhoeae to cationic
antimicrobial peptides. Antimicrob. Agents Chemother. 2014, 58, 4230–4233.
123. Packiam, M.; Yedery, R.D.; Begum, A.A.; Carlson, R.W.; Ganguly, J.; Sempowski, G.D.;
Ventevogel, M.S.; Shafer, W.M.; Jerse, A.E. Phosphoethanolamine decoration of Neisseria
gonorrhoeae lipid a plays a dual immunostimulatory and protective role during experimental
genital tract infection. Infect. Immun. 2014, 82, 2170–2179.
124. Groisman, E.A.; Parra-Lopez, C.; Salcedo, M.; Lipps, C.J.; Heffron, F. Resistance to host
antimicrobial peptides is necessary for Salmonella virulence. Proc. Natl. Acad. Sci. U.S.A. 1992,
89, 11939–11943.
125. Dalebroux, Z.D.; Matamouros, S.; Whittington, D.; Bishop, R.E.; Miller, S.I. PhoPQ regulates
acidic glycerophospholipid content of the Salmonella typhimurium outer membrane. Proc. Natl.
Acad. Sci. U.S.A. 2014, 111, 1963–1968.
126. Matamouros, S.; Miller, S.I. S. Typhimurium strategies to resist killing by cationic antimicrobial
peptides. Biochim. Biophys. Acta 2015, doi: 10.1016/j.bbamem.2015.01.013.
127. Dalebroux, Z.D.; Miller, S.I. Salmonellae PhoPQ regulation of the outer membrane to resist innate
immunity. Curr Opin Microbiol. 2014, 17, 106–113.
128. Cullen, T.W.; Schofield, W.B.; Barry, N.A.; Putnam, E.E.; Rundell, E.A.; Trent, M.S.;
Degnan, P.H.; Booth, C.J.; Yu, H.; Goodman, A.L. Gut Microbiota. Antimicrobial peptide resistance
mediates resilience of prominent gut commensals during inflammation. Science 2015, 347,
170–175.
129. Wang, G.; Hanke, M.L.; Mishra, B.; Lushnikova, T.; Heim, C.E.; Chittezham Thomas, V.;
Bayles, K.W.; Kielian, T. Transformation of human cathelicidin LL-37 into selective, stable, and
potent antimicrobial compounds. ACS Chem. Biol. 2014, 9, 1997–2002.
130. Li, X.; Li, Y.; Han, H.; Miller, D.W.; Wang, G. Solution structures of human LL-37 fragments and
NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region.
J. Am. Chem. Soc. 2006, 128, 5776–5785.
131. Leake, I. IBD: cathelicidin can reverse intestinal fibrosis in models of colitis. Nat. Rev.
Gastroenterol. Hepatol. 2015, 12, 3.
132. Steinstraesser, L.; Lam, M.C.; Jacobsen, F.; Porporato, P.E.; Chereddy, K.K.; Becerikli, M.;
Stricker, I.; Hancock, R.E.; Lehnhardt, M.; Sonveaux, P.; et al. Skin electroporation of a plasmid
encoding hCAP-18/LL-37 host defense peptide promotes wound healing. Mol. Ther. 2014, 22,
734–742.
133. Woo, J.I.; Kil, S.H.; Brough, D.E.; Lee, Y.J.; Lim, D.J.; Moon, S.K. Therapeutic potential of
adenovirus-mediated delivery of beta-defensin 2 for experimental otitis media. Innate Immun.
2015, 21, 215–224.
134. Gonzalez-Curiel, I.; Trujillo, V.; Montoya-Rosales, A.; Rincon, K.; Rivas-Calderon, B.; deHaro-
Acosta, J.; Marin-Luevano, P.; Lozano-Lopez, D.; Enciso-Moreno, J.A.; Rivas-Santiago, B.
1,25-Dihydroxyvitamin D3 induces LL-37 and HBD-2 production in keratinocytes from diabetic
foot ulcers promoting wound healing: An in vitro model. PLoS One 2014, 9, e111355.
135. Mallbris, L.; Edstrom, D.W.; Sundblad, L.; Granath, F.; Stahle, M. UVB upregulates the
antimicrobial protein hCAP18 mRNA in human skin. J. Invest. Dermatol. 2005, 125, 1072–1074.
136. Eda, N.; Shimizu, K.; Suzuki, S.; Tanabe, Y.; Lee, E.; Akama, T. Effects of yoga exercise on
salivary beta-defensin 2. Eur. J. Appl. Physiol. 2013, 113, 2621–2627.
137. Lin, S.P.; Li, C.Y.; Suzuki, K.; Chang, C.K.; Chou, K.M.; Fang, S.H. Green tea consumption after
intense taekwondo training enhances salivary defense factors and antibacterial capacity. PLoS One
2014, 9, e87580.
138. Aboye, T.L.; Ha, H.; Majumder, S.; Christ, F.; Debyser, Z.; Shekhtman, A.; Neamati, N.;
Camarero, J.A. Design of a novel cyclotide-based CXCR4 antagonist with anti-human
immunodeficiency virus (HIV)-1 activity. J. Med. Chem. 2012, 55, 10729–10734.
139. Gunasekera, S.; Foley, F.M.; Clark, R.J.; Sando, L.; Fabri, L.J.; Craik, D.J.; Daly, N.L.
Engineering stabilized vascular endothelial growth factor-a antagonists: synthesis, structural
characterization, and bioactivity of grafted analogues of cyclotides. J. Med. Chem. 2008, 51,
7697–7704.
140. Wang, C.K.; Gruber, C.W.; Cemazar, M.; Siatskas, C.; Tagore, P.; Payne, N.; Sun, G.; Wang, S.;
Bernard, C.C.; Craik, D.J. Molecular grafting onto a stable framework yields novel cyclic peptides
for the treatment of multiple sclerosis. ACS Chem. Biol. 2014, 9, 156–163.
141. Craik, D.J.; Henriques, S.T.; Mylne, J.S.; Wang, C.K. Cyclotide isolation and characterization.
Methods Enzymol. 2012, 516, 37–62.
142. Gunasekera, S.; Daly, N.L.; Anderson, M.A.; Craik, D.J. Chemical synthesis and biosynthesis of
the cyclotide family of circular proteins. IUBMB Life 2006, 58, 515–524.
143. Jia, X.; Kwon, S.; Wang, C.I.; Huang, Y.H.; Chan, L.Y.; Tan, C.C.; Rosengren, K.J.;
Mulvenna, J.P.; Schroeder, C.I.; Craik, D.J. Semienzymatic cyclization of disulfide-rich peptides
using sortase A. J. Biol. Chem. 2014, 289, 6627–6638.
144. Stanger, K.; Maurer, T.; Kaluarachchi, H.; Coons, M.; Franke, Y.; Hannoush, R.N. backbone
cyclization of a recombinant cystine-knot peptide by engineered sortase A. FEBS Lett. 2014, 588,
4487–4496.
145. Lim, K.; Chua, R.R.; Ho, B.; Tambyah, P.A.; Hadinoto, K.; Leong, S.S. Development of a catheter
functionalized by a polydopamine peptide coating with antimicrobial and antibiofilm properties.
Acta Biomater. 2014, 15, 127–138.
146. Godoy-Gallardo, M.; Mas-Moruno, C.; Fernandez-Calderon, M.C.; Perez-Giraldo, C.; Manero, J.M.;
Albericio, F.; Gil, F.J.; Rodriguez, D. Covalent immobilization of hLf1-11 peptide on a titanium
surface reduces bacterial adhesion and biofilm formation. Acta Biomater. 2014, 10, 3522–3534.
147. Lombana, A.; Raja, Z.; Casale, S.; Pradier, C.M.; Foulon, T.; Ladram, A.; Humblot, V.
Temporin-SHa peptides grafted on gold surfaces display antibacterial activity. J. Pept. Sci. 2014,
20, 563–569.
148. Wang, Z.; Han, X.; He, N.; Chen, Z.; Brooks, C.L.,3rd. Molecular structures of C- and N-terminus
cysteine modified cecropin P1 chemically immobilized onto maleimide-terminated self-assembled
monolayers investigated by molecular dynamics simulation. J. Phys. Chem. B 2014, 118,
5670–5680.
149. Mishra, B.; Basu, A.; Chua, R.R.Y.; Saravanan, R.; Tambyah, P.P.; Ho, B.; Chang, M.W.; Leong,
S.S.J. Site specific immobilization of a potent antimicrobial peptide onto silicone catheters:
evaluation against urinary tract infection pathogens. J. Mater. Chem. B, 2014, 2, 1706–1716.
150. Salwiczek, M.; Qu, Y.; Gardiner, J.; Strugnell, R.A.; Lithgow, T.; McLean, K.M.; Thissen, H.
Emerging rules for effective antimicrobial coatings. Trends Biotechnol. 2014, 32, 82–90.
151. Dutta, D.; Ozkan, J.; Willcox, M.D. Biocompatibility of antimicrobial melimine lenses: Rabbit
and human studies. Optom. Vis. Sci. 2014, 91, 570–581.
152. Tan, X.W.; Goh, T.W.; Saraswathi, P.; Nyein, C.L.; Setiawan, M.; Riau, A.; Lakshminarayanan, R.;
Liu, S.; Tan, D.; Beuerman, R.W.; et al. Effectiveness of antimicrobial peptide immobilization for
preventing perioperative cornea implant-associated bacterial infection. Antimicrob. Agents
Chemother. 2014, 58, 5229–5238.
153. Medeiros, K.A.; Joanitti, G.A.; Silva, L.P. Chitosan nanoparticles for dermaseptin peptide delivery
toward tumor cells in vitro. Anticancer Drugs 2014, 25, 323–331.
154. Miao, D.; Jiang, M.; Liu, Z.; Gu, G.; Hu, Q.; Kang, T.; Song, Q.; Yao, L.; Li, W.; Gao, X.; et al.
Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for
antiglioblastoma therapy. Mol. Pharm. 2014, 11, 90–101.
155. Ahmad, A.; Ranjan, S.; Zhang, W.; Zou, J.; Pyykko, I.; Kinnunen, P.K. Novel endosomolytic
peptides for enhancing gene delivery in nanoparticles. Biochim. Biophys. Acta 2015, 1848,
544–553.
156. Keohane, K.; Brennan, D.; Galvin, P.; Griffin, B.T. Silicon microfluidic flow focusing devices for
the production of size-controlled PLGA based drug loaded microparticles. Int. J. Pharm. 2014,
467, 60–69.
157. Chereddy, K.K.; Her, C.H.; Comune, M.; Moia, C.; Lopes, A.; Porporato, P.E.; Vanacker, J.; Lam,
M.C.; Steinstraesser, L.; Sonveaux, P.; et al. PLGA Nanoparticles loaded with host defense peptide
ll37 promote wound healing. J. Control. Release 2014, 194, 138–147.
158. Laverty, G.; McCloskey, A.P.; Gilmore, B.F.; Jones, D.S.; Zhou, J; Xu, B. Ultrashort cationic
naphthalene-derived self-assembled peptides as antimicrobial nanomaterials. Biomacromolecules
2014, 15, 3429–3439.
159. Lillehoj, P.B.; Kaplan, C.W.; He, J.; Shi, W.; Ho, C.M. Rapid, electrical impedance detection of
bacterial pathogens using immobilized antimicrobial peptides. J. Lab. Autom. 2014, 19, 42–49.
160. Etayash, H.; Jiang, K.; Thundat, T.; Kaur, K. impedimetric detection of pathogenic gram-positive
bacteria using an antimicrobial peptide from class IIa bacteriocins. Anal. Chem. 2014, 86,
1693–1700.
161. Kim, H.J.; Brehm-Stecher, B.F. Design and evaluation of peptide nucleic acid probes for specific
identification of Candida albicans. J. Clin. Microbiol. 2015, 53, 511–521.
162. Strauss-Grabo, M.; Atiyem S.; Le, T.; Kretschmar, M. Decade-long use of the antimicrobial
peptide combination tyrothricin does not pose a major risk of acquired resistance with
gram-positive bacteria and Candida spp. Pharmazie 2014, 69, 838–841.
163. Shenkarev, Z.O.; Gizatullina, A.K.; Finkina, E.I.; Alekseeva, E.A.; Balandin, S.V.; Mineev, K.S.;
Arseniev, A.S.; Ovchinnikova, T.V. Heterologous expression and solution structure of defensin
from lentil Lens culinaris. Biochem. Biophys. Res. Commun. 2014, 451, 252–257.
164. De Medeiros, L.N.; Angeli, R.; Sarzedas, C.G.; Barreto-Bergter, E.; Valente, A.P.; Kurtenbach, E.;
Almeida, F.C. Backbone dynamics of the antifungal Psd1 pea defensin and its correlation with
membrane interaction by NMR spectroscopy. Biochim. Biophys. Acta 2010, 1798, 105–113.
165. Neves de Medeiros, L.; Domitrovic, T.; Cavalcante de Andrade, P.; Faria, J.; Barreto Bergter, E.;
Weissmüller, G.; Kurtenbach, E. Psd1 binding affinity toward fungal membrane components as
assessed by SPR: The role of glucosylceramide in fungal recognition and entry. Biopolymers 2014,
102, 456–464.
166. De Paula, V.S.; Pomin, V.H.; Valente, A.P. Unique properties of human β-defensin 6 (hBD6) and
glycosaminoglycan complex: sandwich-like dimerization and competition with the chemokine
receptor 2 (CCR2) binding site. J. Biol. Chem. 2014, 289, 22969–22979.
167. Forde, E.; Humphreys, H.; Greene, C.M.; Fitzgerald-Hughes, D.; Devocelle, M. Potential of host
defense peptide prodrugs as neutrophil elastase-dependent anti-infective agents for cystic fibrosis.
Antimicrob. Agents Chemother. 2014, 58, 978–985.
168. Forde, E.; Devocelle, M. Pro-moieties of antimicrobial peptide prodrugs. Molecules 2015, 20,
1210–1227.
169. Neumann, A.; Völlger, L.; Berends, E.T.; Molhoek, E.M.; Stapels, D.A.; Midon, M.; Friães, A.;
Pingoud, A.; Rooijakkers, S.H.; Gallo, R.L.; et al. Novel role of the antimicrobial peptide LL-37
in the protection of neutrophil extracellular traps against degradation by bacterial nucleases.
J. Innate Immun. 2014, 6, 860–868.
170. Sol, A.; Skvirsky, Y.; Nashef, R.; Zelentsova, K.; Burstyn-Cohen, T.; Blotnick, E.; Muhlrad, A.;
Bachrach, G. Actin enables the antimicrobial action of LL-37 peptide in the presence of microbial
proteases. J. Biol. Chem. 2014, 289, 22926–22941.
171. Sol, A.; Wang, G.; Blotnick, E.; Golla, R.; Bachrach, G. Interaction of the core fragments of the
LL-37 host defense peptide with actin. RSC Adv. 2015, 5, 9361–9367.
172. Svensson, D.; Westman, J.; Wickstrom, C.; Jonsson, D.; Herwald, H.; Nilsson, B.O. Human
Endogenous Peptide p33 Inhibits Detrimental Effects of LL-37 on Osteoblast Viability.
J. Periodontal. Res. 2015, 50, 80–88.
173. Hiemstra, T.F.; Charles, P.D.; Gracia, T.; Hester, S.S.; Gatto, L.; Al-Lamki, R.; Floto, R.A.;
Su, Y.; Skepper, J.N.; Lilley, K.S.; et al. Human Urinary Exosomes as Innate Immune Effectors.
J. Am. Soc. Nephrol. 2014, 50, 80–88.
174. Carmona-Ribeiro, A.M.; de Melo Carrasco, L.D. Novel formulations for antimicrobial peptides.
Int. J. Mol. Sci. 2014, 15, 18040–18083.
175. Pina, A.S.; Batalha, I.L.; Fernandes, C.S.; Aoki, M.A.; Roque, A.C. Exploring the potential of
magnetic antimicrobial agents for water disinfection. Water Res. 2014, 66, 160–168.
176. Silva, R.R.; Avelino, K.Y.; Ribeiro, K.L.; Franco, O.L.; Oliveira, M.D.; Andrade, C.A. Optical
and dielectric sensors based on antimicrobial peptides for microorganism diagnosis. Front.
Microbiol. 2014, 5, 443.
177. Otter, J.A.; Vickery, K.; Walker, J.T.; deLancey Pulcini, E.; Stoodley, P.; Goldenberg, S.D.;
Salkeld, J.A.; Chewins, J.; Yezli, S.; Edgeworth, J.D. Surface-attached cells, biofilms and biocide
susceptibility: implications for hospital cleaning and disinfection. J. Hosp. Infect. 2015, 89,
16–27.
178. Pimentel-Filho Nde, J.; Martins, M.C.; Nogueira, G.B.; Mantovani, H.C.; Vanetti, M.C. Bovicin
HC5 and nisin reduce Staphylococcus aureus adhesion to polystyrene and change the
hydrophobicity profile and gibbs free energy of adhesion. Int. J. Food Microbiol. 2014, 190, 1–8.
179. Dong, X.; McCoy, E.; Zhang, M.; Yang, L. Inhibitory effects of nisin-coated multi-walled carbon
nanotube sheet on biofilm formation from Bacillus anthracis spores. J. Environ. Sci. (China) 2014,
26, 2526–2534.
180. Singh, A.P.; Preet, S.; Rishi, P. Nisin/β-Lactam adjunct therapy against Salmonella enterica
serovar Typhimurium: a mechanistic approach. J. Antimicrob. Chemother. 2014, 69, 1877–1887.
181. Dosler, S.; Karaaslan, E. Inhibition and destruction of Pseudomonas aeruginosa biofilms by
antibiotics and antimicrobial peptides. Peptides 2014, 62, 32–37.
182. Maiti, S.; Patro, S.; Purohit, S.; Jain, S.; Senapati, S.; Dey, N. Effective control of Salmonella
infections by employing combinations of recombinant antimicrobial human β-defensins hBD-1
and hBD-2. Antimicrob Agents Chemother. 2014, 58, 6896–6903.
183. Donelli, G.; Francolini, I.; Romoli, D.; Guaglianone, E.; Piozzi, A.; Ragunath, C.; Kaplan, J.B.
Synergistic activity of dispersin B and cefamandole nafate in inhibition of staphylococcal biofilm
growth on polyurethanes. Antimicrob Agents Chemother. 2007, 51, 2733–2740.
184. Tong, Z.; Zhang, L.; Ling, J.; Jian, Y.; Huang, L.; Deng, D. An in vitro study on the effect of free
amino acids alone or in combination with nisin on biofilms as well as on planktonic bacteria of
Streptococcus mutans. PLoS One 2014, 9, e99513.
185. De la Fuente-Nunez, C.; Reffuveille, F.; Haney, E.F.; Straus, S.K.; Hancock, R.E. Broad-Spectrum
anti-biofilm peptide that targets a cellular stress response. PLoS Pathog. 2014, 10, e1004152.
186. Bommarius, B.; Anyanful, A.; Izrayelit, Y.; Bhatt, S.; Cartwright, E.; Wang, W.; Swimm, A.I.;
Benian, G.M.; Schroeder, F.C.; Kalman, D. A family of indoles regulate virulence and Shiga toxin
production in pathogenic E. coli. PLoS One. 2013, 8, e54456.
187. Scopel, M.; Abraham, W.R.; Antunes, A.L.; Henriques, A.T.; Macedo, A.J. Mevalonolactone: an
inhibitor of Staphylococcus epidermidis adherence and biofilm formation. Med. Chem. 2014, 10,
246–251.
188. Liaqat, I.; Bachmann, R.T.; Edyvean, R.G. Type 2 quorum sensing monitoring, inhibition and
biofilm formation in marine microrganisms. Curr. Microbiol. 2014, 68, 342–351.
189. Pereira, U.A.; Barbosa, L.C.; Maltha, C.R.; Demuner, A.J.; Masood, M.A.; Pimenta, A.L.
γ-Alkylidene-γ-lactones and isobutylpyrrol-2(5H)-ones analogues to rubrolides as inhibitors of
biofilm formation by gram-positive and gram-negative bacteria. Bioorg. Med. Chem. Lett. 2014,
24, 1052–1056.
© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/4.0/).

Pharmaceuticals: Antimicrobial Peptides in 2014

Uploaded by

Copyright:

Available Formats

Pharmaceuticals: Antimicrobial Peptides in 2014

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Pharmaceuticals: Antimicrobial Peptides in 2014

Uploaded by

Copyright:

Available Formats

Pharmaceuticals 2015, 8, 123-150; doi:10.

Antimicrobial Peptides in 2014

* Author to whom correspondence should be addressed; E-Mail: [email protected];

Academic Editor: Jean Jacques Vanden Eynde

Received: 11 February 2015 / Accepted: 17 March 2015 / Published: 23 March 2015

Keywords: antimicrobial peptide; bacterial detection; biofilms; mechanism of action;

2. New Host Defense Peptides Reported in 2014

Table 1. Select antimicrobial peptides discovered in 2014.

3. New Light on Known Human Antimicrobial Peptides

4. Mechanisms of Action of Antimicrobial Peptides and Genetic Basis of Bacterial Resistance

4.1. Peptide at Work

Figure 1. Mechanisms of action of antimicrobial peptides in 2014. Membrane channel

Table 2. Mechanistic similarities between thioether-bonded lantibiotics and disulfide-boned peptides.

4.2.1. Gram-Positive Bacteria

4.2.2. Gram-Negative Bacteria

5. Potential Applications of Antimicrobial Peptides

5.1. Toward Therapeutic Uses

5.2. Peptide Surface Coating

5.3. Nanoparticle-Based Drug Delivery Systems

5.4. Biosensors and Detection

No conflicts of interest was declared.

1. Zasloff, M. Antimicrobial peptides of multicellullar organisms. Nature 2002, 415, 359–365.

You might also like